| Literature DB >> 32968131 |
Amandine Crombé1,2,3,4, Michèle Kind5, David Fadli5, François Le Loarer6,7, Antoine Italiano6,8, Xavier Buy5, Olivier Saut9,6.
Abstract
Intensity harmonization techniques (IHT) are mandatory to homogenize multicentric MRIs before any quantitative analysis because signal intensities (SI) do not have standardized units. Radiomics combine quantification of tumors' radiological phenotype with machine-learning to improve predictive models, such as metastastic-relapse-free survival (MFS) for sarcoma patients. We post-processed the initial T2-weighted-imaging of 70 sarcoma patients by using 5 IHTs and extracting 45 radiomics features (RFs), namely: classical standardization (IHTstd), standardization per adipose tissue SIs (IHTfat), histogram-matching with a patient histogram (IHTHM.1), with the average histogram of the population (IHTHM.All) and plus ComBat method (IHTHM.All.C), which provided 5 radiomics datasets in addition to the original radiomics dataset without IHT (No-IHT). We found that using IHTs significantly influenced all RFs values (p-values: < 0.0001-0.02). Unsupervised clustering performed on each radiomics dataset showed that only clusters from the No-IHT, IHTstd, IHTHM.All, and IHTHM.All.C datasets significantly correlated with MFS in multivariate Cox models (p = 0.02, 0.007, 0.004 and 0.02, respectively). We built radiomics-based supervised models to predict metastatic relapse at 2-years with a training set of 50 patients. The models performances varied markedly depending on the IHT in the validation set (range of AUROC from 0.688 with IHTstd to 0.823 with IHTHM.1). Hence, the use of intensity harmonization and the related technique should be carefully detailed in radiomics post-processing pipelines as it can profoundly affect the reproducibility of analyses.Entities:
Mesh:
Year: 2020 PMID: 32968131 PMCID: PMC7511974 DOI: 10.1038/s41598-020-72535-0
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Figure 1Study pipeline. HM histogram matching, IHT intensity harmonization technique, No-IHT no use of IHT before extracting radiomics features, RF radiomics features, WI weighted imaging.
Clinical and pathological features of the study population.
| Characteristics | No. of patients |
|---|---|
| Median (range) | 58 (19–84) |
| Men | 38/70 (54.3) |
| Women | 32/70 (45.7) |
| PS 0 | 55/70 (78.6) |
| PS 1 | 15/70 (21.4) |
| Undifferentiated sarcoma | 31/70 (44.3) |
| Synovial sarcoma | 8/70 (11.4) |
| Rhabdomyosarcoma | 8/70 (11.4) |
| Leiomyosarcoma | 6/70 (8.6) |
| Myxoid/round cells liposarcoma | 6/70 (8.6) |
| Pleomorphic sarcoma | 3/70 (4.3) |
| Other sarcomas | 8/70 (11.4) |
| median (range) | 106 (40–273) |
| median (range) | 220 (10.2–3,084) |
| Trunk | 12/70 (17.1) |
| Shoulder girdle | 9/70 (12.9) |
| Upper limb | 9/70 (12.9) |
| Pelvic girdle | 5/70 (7.1) |
| Lower limb | 35/70 (50) |
| Deep-seated | 65/70 (92.9) |
| Superficial and aponeurotic | 5/70 (7.1) |
| 4 cycles | 18/70 (25.7) |
| 5–6 cycles | 52/70 (74.3) |
| Anthracycline-ifosfamide | 64/70 (91.4) |
| Doxorubicine | 6/70 (8.6) |
| No | 5/70 (7.1) |
| Yes | 65/70 (92.9) |
| R0 | 41/70 (58.5) |
| R1 | 29/70 (41.4) |
| Good | 16/70 (22.9) |
| Poor | 54/70 (77.1) |
Results are number of patients with percentage in parentheses, except for age, longest diameter and volume that are expressed as median with range in parentheses.
WHO PS World health organization performance status.
Summary of the per-radiomics features (RFs) analysis.
| Post-hoc comparisonsa | No. of significant differencesb |
|---|---|
| IHTHM.All vs IHTfat | 31/45 (68.9%) |
| IHTHM.All.C vs IHTfat | 30/45 (66.7%) |
| IHTHM.1 vs IHTfat | 30/45 (66.7%) |
| IHTstd vs IHTHM.All | 28/45 (62.2%) |
| No-IHT vs IHTfat | 28/45 (62.2%) |
| No-IHT vs IHTHM.1 | 28/45 (62.2%) |
| No-IHT vs IHTHM.All | 27/45 (60%) |
| No-IHT vs IHTHM.All.C | 27/45 (60%) |
| IHTstd vs IHTHM.All.C | 27/45 (60%) |
| IHTstd vs No-IHT | 23/45 (51.1%) |
| IHTstd vs IHTfat | 20/45 (44.4%) |
| IHTstd vs IHTHM.1 | 19/45 (42.2%) |
| IHTHM.1 vs IHTHM.All.C | 14/45 (31.1%) |
| IHTHM.All.C vs IHTHM.All | 13/45 (28.9%) |
| IHTHM.1 vs IHTHM.All | 6/45 (13.3%) |
aPost-Hoc comparisons correspond to the post-hoc Bonferroni-corrected Tukey tests for repeated-measures ANOVAs where the influence of the intensity harmonization techniques (IHT) on the 45 RFs was investigated.
bThe number (no.) of significant differences corresponds to the number of RFs that were significantly different in a given post-hoc comparisons between 2 IHTs or the raw radiomics dataset, without IHT—named No-IHT (with percentage over the total number of RFs in parentheses).
HM histogram matching, No. number.
Figure 2Intra-class correlation coefficients (ICC) of the radiomics features (RFs) depending on the intensity harmonization technique (IHT). Results are given with 95% confidence interval.
Comparisons of the different dendrograms obtained by hierarchical clustering of the radiomics features with the 6 datasets depending on the intensity harmonization technique (IHT). (a) Corresponds to the Cohen’s Kappa index ranging from 0 (completely different clustering assignements) to 1 (exactly the same clustering assignements). (b) Corresponds to the the Baker’s gamma coefficient ranging from 0 (completely different dendrograms) to 1 (exactly the same two dendrograms).
| (a) | IHTfat | IHTstd | IHTHM.1 | IHTHM.All | IHTHM.All.C | (b) | IHTfat | IHTstd | IHTHM.1 | IHTHM.All | IHTHM.All.C |
|---|---|---|---|---|---|---|---|---|---|---|---|
| No-IHT | 0.40 | 0.33 | 0.18 | 0.39 | 0.35 | No-IHT | 0.19 | 0.11 | 0.05 | 0.05 | 0.07 |
| IHTfat | 0.33 | 0.23 | 0.36 | 0.43 | IHTfat | 0.14 | 0.15 | 0.17 | 0.18 | ||
| IHTstd | 0.25 | 0.51 | 0.67 | IHTstd | 0.11 | 0.30 | 0.42 | ||||
| IHTHM.1 | 0.40 | 0.44 | IHTHM.1 | 0.26 | 0.29 | ||||||
| IHTHM.All | 0.75 | IHTHM.All | 0.55 |
Figure 3Comparisons of the hierarchical clustering results based on radiomics features from different datasets depending on the intensity harmonization technique (IHT) with: (a) the highest divergence, and (b) the lowest divergence. The dendrograms were obtained according to the following IHTs: histogram matching (HM) with a randomly-chosen normalized histogram of a patient (IHTHM1) versus no use of harmonization technique (No-IHT); and HM with the average normalized histogram of the study population (IHTHM.All) versus IHTHM.All combined with ComBat harmonization method (IHTHM.All.C). By convention, cluster-1 (in blue) corresponds to the group of patients with the best prognosis regarding metastatic-relapse free survival.
Figure 4Kaplan–Meier curves for metastatic-relapse free survival depending on unsupervised clustering results based on radiomics features obtained with the different intensity harmonization techniques (IHT) or no use of harmonization technique (No-IHT).
Unsupervised analysis based on radiomics features (RFs)—Prognostic value of the clustering results depending on the intensity harmonization technique (IHT).
| Intensity harmonization technique | Clustering result | No. of patients | No. of events | 2-years survival probability | Univariate analysis | Multivariate cox modelinga | |||
|---|---|---|---|---|---|---|---|---|---|
| Log-rank p-value | Concordance-index | HR | p-value | Concordance-index | |||||
| No-IHT | Cluster-1 | 51 | 22 | 64.7 (52.8–79.3) | 0.3 | 0.55 (0.50–0.59) | – | – | 0.75 (0.71–0.79) |
| Cluster-2 | 19 | 10 | 52.6 (34.4–80.6) | 2.64 (1.15–6.04) | 0.02* | ||||
| IHTfat | Cluster-1 | 53 | 23 | 62.3 (50.5–76.8) | 0.6 | 0.51 (0.47–0.55) | – | – | 0.72 (0.67–0.76) |
| Cluster-2 | 17 | 9 | 58.8 (39.5–87.6) | 1.65 (0.70–3.89) | 0.3 | ||||
| IHTstd | Cluster-1 | 30 | 11 | 70 (55.4–88.5) | 0.1 | 0.55 (0.50–0.60) | – | – | 0.75 (0.72–0.79) |
| Cluster-2 | 40 | 21 | 55 (41.6–72.8) | 3.26 (1.48–7.71) | 0.007* | ||||
| IHTHM.1 | Cluster-1 | 50 | 22 | 64 (52–78.8) | 0.6 | 0.52 (0.48–0.56) | – | – | 0.71 (0.67–0.75) |
| Cluster-2 | 20 | 10 | 55 (37–81.8) | 1.52 (0.66–3.49) | 0.3 | ||||
| IHTHM.All | Cluster-1 | 20 | 5 | 80 (64.3–99.6) | 0.03* | 0.58 (0.54–0.62) | – | – | 0.75 (0.70–0.79) |
| Cluster-2 | 50 | 27 | 54 (41.8–69.7) | 4.72 (1.64–13.56) | 0.004** | ||||
| IHTHM.All.C | Cluster-1 | 28 | 10 | 67.9 (52.6–87.6) | 0.3 | 0.53 (0.51–0.55) | – | – | 0.73 (0.68–0.77) |
| Cluster-2 | 42 | 22 | 57.1 (44–74.3) | 2.89 (1.19–7.05) | 0.02* | ||||
Results for 2-years survival probability, hazard ratio and concordance-index are given with 95% confidence interval.
aMultivariate Cox modeling were adjusted for the following clinical and pathological covariables: performance status, histotype, initial longest diameter of the tumor, type of neoadjuvant chemotherapy, number of cycles of chemotherapy, surgical margins, histological response and adjuvant Radiotherapy.
HM histogram matching, HR hazard ratio, No: number.
*: p < 0.05, **: p < 0.005, ***: p < 0.001.
Accuracy and area under the ROC curves (AUROC) of the supervised models in repeated cross validation (training cohort) and in the testing/validation independent cohort, depending on the 5 intensity harmonization techniques (IHTs) or the lack of IHT (named No-IHT).
| Intensity harmonization technique | Best hyperparameter tuning | Training cohort (results in repeated cross-validation) | Testing cohort | ||
|---|---|---|---|---|---|
| Accuracy | AUROC | Accuracy | AUROC | ||
| No-IHT | Alpha = 0.883 Lambda = 0.114 | 0.56 (0.52–0.64) | 0.57 (0.52–0.60) | 0.75 (0.51–0.89) | 0.76 (0.50–1.0) |
| IHTfat | Alpha = 0.226, Lambda = 0.048 | 0.60 (0.64–0.55) | 0.68 (0.63–0.73) | 0.75 (0.51–0.91) | 0.80 (0.56–1.0) |
| IHTstd | Alpha = 0.384, Lambda = 0.086 | 0.63 (0.59–0.55) | 0.64 (0.59–0.69) | 0.70 (0.46–0.88) | 0.69 (0.41–0.89) |
| IHTHM.1 | Alpha = 0.394, Lambda = 0.200 | 0.62 (0.66–0.59) | 0.69 (0.64–0.74) | 0.75 (0.51–0.91) | 0.82 (0.59–1) |
| IHTHM.All | Alpha = 0.338, Lambda = 0.384 | 0.61 (0.63–0.58) | 0.71 (0.66–0.76) | 0.60 (0.36–0.81) | 0.77 (0.52–1) |
| IHTHM.All.C | Alpha = 0.166 Lambda = 0.840 | 0.58 (0.57–0.59) | 0.68 (0.63–0.73) | 0.60 (0.36–0.81) | 0.71 (0.44–0.97) |
Results are giving with 95% confidence interval.
Figure 5ROC curves for the best and worse supervised models to predict metastatic relapse within 2 years after the end of initial treatment in the testing cohort (built on the radiomics features from the IHTHM.1 and IHTstd datasets, respectively). The ROC curve of the final model without using harmonization technique (No-IHT) is also shown for comparison.